Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 57,622 | 58,766 | 62,472 | 57,336 | 46,497 |
| Cost of Goods | 12,535 | 9,383 | 9,919 | 7,625 | 20,364 |
| Gross Profit | 45,087 | 49,383 | 52,553 | 49,711 | 26,133 |
| Operating Expenses | 54,175 | 45,317 | 39,383 | 36,822 | 40,803 |
| Operating Income | -8,553 | 4,449 | 14,089 | 13,514 | -14,306 |
| Interest Expense | 4,827 | 4,748 | 6,834 | 7,770 | 6,877 |
| Other Income | 2,145 | 1,454 | -7,008 | 368 | -1,621 |
| Pre-tax Income | -11,235 | 1,155 | 247 | 6,112 | -22,804 |
| Income Tax | 1,009 | 615 | N/A | N/A | N/A |
| Net Income Continuous | -12,244 | 540 | 247 | 6,112 | -22,804 |
| Net Income | $-12,244 | $540 | $247 | $6,112 | $-22,804 |
| EPS Basic Total Ops | -0.05 | 0.00 | 0.00 | 0.03 | -0.10 |
| EPS Basic Continuous Ops | -0.05 | 0.00 | 0.00 | 0.03 | -0.11 |
| EPS Diluted Total Ops | -0.05 | 0.00 | 0.00 | 0.03 | -0.10 |
| EPS Diluted Continuous Ops | -0.05 | 0.00 | 0.00 | 0.03 | -0.11 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.00 | 0.00 | 0.03 | -0.10 |
| EBITDA(a) | $-8,232 | $4,767 | $14,405 | $13,828 | $-4,961 |